Effect of a Patient-Centered Decision App on TOLAC (PROCEED)

January 12, 2021 updated by: University of California, San Francisco

Effect of a Patient-Centered Decision App on TOLAC: An RCT

Cesarean delivery (CD) is the most common inpatient surgery in the US, accounting for nearly one third of births annually. In the last decade, the CD rate has increased by approximately 50%, with almost 1.3 million procedures performed in 2012 (Hamilton 2013). CDs have been associated with an increase in major maternal morbidity (Silver 2010), with corresponding increases in length of inpatient care following delivery and frequency of hospital readmission (Lydon-Rochelle 2000). Organizations including Healthy People, the American College of Obstetricians and Gynecologists (ACOG), and the American College of Nurse Midwives have targeted reducing the CD rate as an important public health goal for more than a decade; however, identifying interventions to achieve this goal has proven challenging.

Repeat CDs are a significant contributor to the increased cesarean rate, resulting from the combination of a rising rate of primary CD and a decreasing rate of vaginal birth after cesarean (VBAC), which declined from a high of 28.3% in 1996 (Guide 2010) to 9.2% in 2010 (Hamilton 2011). Why the VBAC rate has decreased so dramatically remains a subject of debate; the extent to which these changes are driven by patient preferences is not known. An NIH consensus conference statement noted that "the informed consent process for TOLAC and Elective Repeat Cesarean Delivery (ERCD) should be evidence-based, minimize bias, and incorporate a strong emphasis on the values and preferences of pregnant women," and recommended "interprofessional collaboration to refine, validate, and implement decision-making and risk assessment tools" to accomplish that goal (Cunningham 2010).

Our group recently created a decision tool, which we refer to as the Prior CD App (PCDA), to help English- or Spanish-speaking TOLAC-eligible women delivering at hospitals that offer TOLAC consider individualized risk assessments, incorporate their values and preferences, and participate in a shared decision making process with their providers to make informed decisions about delivery approach. We are now conducting a randomized study of the effect of a Prior CD App on TOLAC and VBAC rates, as well as a number of aspects of decision quality.

Study Overview

Study Type

Interventional

Enrollment (Actual)

1485

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • San Francisco, California, United States, 94143
        • UCSF
      • San Francisco, California, United States, 94110
        • Sutter Health, California Pacific Medical Center, St. Luke's Campus
      • San Rafael, California, United States, 94901
        • Marin Community Clinic
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Northwestern Memorial Hospital
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Women with exactly one prior Cesarean Delivery.
  2. Current singleton pregnancy.
  3. Gestational age, 12-24 weeks.
  4. English or Spanish speaker.
  5. Must be receiving prenatal care at one of the participating centers.

Exclusion Criteria:

  1. Contraindications to vaginal delivery (e.g., placenta previa, prior classical cesarean, previous uterine rupture).
  2. Prior VBAC.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prior CD Decision App (PCDDA)
Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
No Intervention: Usual Care - No App
Women randomized to the Usual Care - No App group will simply continue with usual care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Who Underwent a Trial of Labor After Cesarean (TOLAC) Delivery
Time Frame: 0-8 weeks after delivery
Number of participants who underwent a trial of labor after cesarean (TOLAC) delivery, as noted in the medical record.
0-8 weeks after delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Who Underwent Vaginal Birth After Cesarean (VBAC)
Time Frame: 0 to 8 weeks after delivery
Number of participants who underwent vaginal birth after cesarean (VBAC), as noted in the medical record.
0 to 8 weeks after delivery
Knowledge About TOLAC and ERCD
Time Frame: Approx 34-37 weeks gestation
8-item knowledge scale, administered during telephone interview. Scores ranged from 0 to 8 with higher scored indicating greater knowledge.
Approx 34-37 weeks gestation
Decisional Conflict
Time Frame: Approx 34-37 weeks gestation
16-item Decisional Conflict Scale with 5 response categories, administered during telephone interview. Scoring: total scale-0 (no decisional conflict) to 100 (extreme decisional conflict) lower values indicate lower decisional conflict.
Approx 34-37 weeks gestation
Shared Decision Making
Time Frame: Approx 34-37 weeks gestation

9-item Shared Decision Making Scale, administered during telephone interview.

Shared decision-making was measured using the 9-item Shared Decision Making Questionnaire (SDM-Q-9), a psychometrically evaluated tool. The core instrument consists of nine statements, which can be rated on a six-point scale from "completely disagree" (0) to "completely agree" (5). The Shared Decision Score can range from 0 to 100, with higher scores indicating more shared decision-making.

Approx 34-37 weeks gestation
Decision Self-Efficacy
Time Frame: Approx 34-37 weeks gestation

11-item Decisional Self-Efficacy Scale, administered during telephone interview.

The total score is calculated by summing the 11 items, dividing by 11 and multiplying by 25. Scores range from 0 (not confident) to 100 (extremely confident).

Approx 34-37 weeks gestation
Decision Satisfaction
Time Frame: Approx 34-37 weeks gestation

6-item Satisfaction with Decision Scale, administered during telephone interview.

Satisfaction With Decision Scale scores range from 0 to 5, with higher scores indicating more satisfaction.

Approx 34-37 weeks gestation
Maternal Major Morbidity
Time Frame: Collected 0 to 8 weeks after delivery.
Defined as any of: uterine rupture, hysterectomy, surgical injury (bowel, bladder/ureter, or other), maternal death, as noted in the medical record for her delivery.
Collected 0 to 8 weeks after delivery.
Maternal Minor Morbidity
Time Frame: Collected 0 to 8 weeks after delivery.
Defined as any of: blood transfusion, postpartum febrile morbidity (endometritis, cellulitis, urinary tract infection, or other infection), as noted in the medical record for her delivery.
Collected 0 to 8 weeks after delivery.
3rd or 4th Degree Lacerations
Time Frame: Collected 0 to 8 weeks after delivery.
3rd or 4th degree lacerations, as noted in the medical record for her delivery.
Collected 0 to 8 weeks after delivery.
Perinatal Death or Hypoxic-ischemic Encephalopathy
Time Frame: Collected 0 to 8 weeks after delivery.
Stillbirth/fetal demise (antepartum or intrapartum), neonatal death, HIE, as noted in the medical record for her delivery.
Collected 0 to 8 weeks after delivery.
Neonatal Respiratory Morbidity
Time Frame: Collected 0 to 8 weeks after delivery.
Respiratory morbidity requiring CPAP or intubation, as noted in the medical record for her delivery.
Collected 0 to 8 weeks after delivery.
Neonatal Intensive Care Unit (NICU) Admission
Time Frame: Collected 0 to 8 weeks after delivery.
Neonatal intensive care unit (NICU) admission, as noted in the medical record for her delivery.
Collected 0 to 8 weeks after delivery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Actual)

June 1, 2019

Study Completion (Actual)

June 1, 2019

Study Registration Dates

First Submitted

December 15, 2015

First Submitted That Met QC Criteria

December 31, 2015

First Posted (Estimate)

January 5, 2016

Study Record Updates

Last Update Posted (Actual)

February 2, 2021

Last Update Submitted That Met QC Criteria

January 12, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 1R01HD078748 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy

Clinical Trials on Prior CD Decision App

3
Subscribe